RHYTHM PHARMACEUTICALS, INC. 8-K

What Happened
On March 26, 2026, Rhythm Pharmaceuticals, Inc. (RYTM) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending expansion of the marketing authorization for IMCIVREE (setmelanotide). The recommendation covers treatment of obesity and control of hunger in adults and children 4 years and older with acquired hypothalamic obesity (HO) due to hypothalamic injury or impairment. The company furnished a press release as Exhibit 99.1 in its Form 8-K. The CHMP opinion will be reviewed by the European Commission (EC), with a final decision anticipated in the second quarter of 2026.

Key Details

• Date filed: March 26, 2026 (Current Report on Form 8-K).
• Product: IMCIVREE (setmelanotide).
• Indication recommended by CHMP: obesity and control of hunger for adults and children aged ≥4 with acquired hypothalamic obesity due to hypothalamic injury/impairment.
• Next regulatory step: EC review of CHMP opinion; final EC decision expected Q2 2026.
• Filing note: press release furnished as Exhibit 99.1; the 8-K includes standard forward‑looking statements and references Rhythm’s 2025 Form 10-K risk factors.

Why It Matters
A positive CHMP opinion is a key regulatory milestone toward European approval for an expanded indication of IMCIVREE. If the European Commission grants the expanded marketing authorization, Rhythm could market IMCIVREE in the EU for acquired hypothalamic obesity in the specified age group, potentially increasing the drug’s addressable market. However, this is not a final approval until the EC decision; investors should watch for the EC ruling expected in Q2 2026 and consider the regulatory and commercialization risks noted in Rhythm’s filings.